Your browser doesn't support javascript.
loading
Discovery of Potent, Highly Selective, and In Vivo Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing.
Pissot Soldermann, Carole; Simic, Oliver; Renatus, Martin; Erbel, Paulus; Melkko, Samu; Wartmann, Markus; Bigaud, Marc; Weiss, Andreas; McSheehy, Paul; Endres, Ralf; Santos, Paulo; Blank, Jutta; Schuffenhauer, Ansgar; Bold, Guido; Buschmann, Nicole; Zoller, Thomas; Altmann, Eva; Manley, Paul W; Dix, Ina; Buchdunger, Elisabeth; Scesa, Julien; Quancard, Jean; Schlapbach, Achim; Bornancin, Frédéric; Radimerski, Thomas; Régnier, Catherine H.
Affiliation
  • Pissot Soldermann C; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Simic O; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Renatus M; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Erbel P; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Melkko S; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Wartmann M; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Bigaud M; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Weiss A; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • McSheehy P; Basilea Pharmaceutica, CH-4002 Basel, Switzerland.
  • Blank J; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Schuffenhauer A; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Bold G; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Buschmann N; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Zoller T; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Altmann E; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Manley PW; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Dix I; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Buchdunger E; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Scesa J; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Quancard J; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Schlapbach A; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Bornancin F; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
  • Radimerski T; Basilea Pharmaceutica, CH-4002 Basel, Switzerland.
  • Régnier CH; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.
J Med Chem ; 63(23): 14576-14593, 2020 12 10.
Article in En | MEDLINE | ID: mdl-33252239
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urea / Caspase Inhibitors / Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein / Neoplasms Limits: Animals / Female / Humans / Male Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2020 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urea / Caspase Inhibitors / Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein / Neoplasms Limits: Animals / Female / Humans / Male Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2020 Document type: Article Affiliation country: Country of publication: